Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores

Gastroenterology Aug 01, 2019

Ioannou GN, Beste LA, Green PK, et al. - Whether the risk of hepatocellular carcinoma (HCC) decreases over time following hepatitis C virus (HCV) eradication is not clear, so researchers evaluated changes in annual HCC incidence overtime after HCV eradication and recognized dynamic HCC risk markers. Forty-eight thousand one hundred thirty-five patients who started HCV antiviral treatment from 2000 through 2015 and achieved a sustained virologic response (SVR) in the Veterans Health Administration (29,033 treated with direct-acting antiviral (DAA) agents and 19,102 treated with interferon-based regimens) were identified. According to findings, cirrhosis patients with HCV infection treatment prior to an SVR continue to be at high risk for HCC (> 2%/year) for several years, even if their fibrosis-4 (FIB-4) score decreases and they should continue to be monitored. Patients without cirrhosis but with FIB-4 scores ≥3.25 have a sufficiently high risk to warrant HCC monitoring, particularly if FIB-4 remains ≥3.25 post-SVR.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen